Eli Lilly LLY and partner Incyte INCY announced that a late-stage study evaluating oral baricitinib in adolescent patients ...

Eli Lilly And Co (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) said adolescent patients with severe alopecia areata (AA) ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to ...

A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...

Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...

Sporting a white dress and a red headscarf, Japan’s version of a Barbie doll has a new look to battle the stigma of alopecia areata, an intractable immune disease that causes patchy hair loss.

Alopecia areata occurs when the body’s natural defense, the immune system, attacks the hair follicles and causes the hair to fall out. It tends to lead to round or oval bald patches on the scalp ...

AA is an immune system condition that causes patchy hair loss on the scalp, face, and sometimes other body areas, which can progress over time. At Week 36: 60.0% of patients receiving baricitinib ...